Damora Therapeutics (DMRA) Return on Capital Employed (2020 - 2026)

Damora Therapeutics has reported Return on Capital Employed for 7 years, with the latest figure at 63.9% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 6661.0% year-over-year to 63.9%; the trailing twelve-month figure through Mar 2026 stood at 63.9% (up 6661.0% YoY), and the FY2025 full-year result was 177.61%, down 9354.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 63.9%, up from 182.52% in the prior quarter.
• The five-year high for Return on Capital Employed was 51.32% in Q1 2022, with the low at 182.52% in Q4 2025.
• Historically, Return on Capital Employed has averaged 107.29% across 5 years, with a median of 104.09% in 2023.
• Annual changes were most pronounced in 2025 — Return on Capital Employed sank 7439 bps — and 2026, when it surged 6661 bps.
• Damora Therapeutics' Return on Capital Employed stood at 92.04% in 2022, then retreated by 13 bps to 104.09% in 2023, then decreased by 12 bps to 116.83% in 2024, then slumped by 56 bps to 182.52% in 2025, then surged by 65 bps to 63.9% in 2026.
• The last three Return on Capital Employed figures came in at 63.9% (Q1 2026), 182.52% (Q4 2025), and 169.73% (Q3 2025), per Business Quant data.